
Ellipses Pharma licences SRB22 from SunRock Biopharma
Under the agreement, British Ellipses Pharma Ltd has been granted global rights to develop and commercialise SBR22 (which it renamed to EP0017) from...

Swedish Bioinvent issues shares worth SEK299m (USD28m)
“A key prerequisite for BioInvent’s growing pipeline of immuno-oncology drug candidates is strong financial resources, securing that the clinical...

Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
Swiss Urovant Science, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., will receive up to USD $75m in upfront payment, regulatory, and sales...

InflaRX set to file for MAA for vilobelimab
Following talks with the US regulatory authority FDA, InflaRx N.V. announced plans to file its first-in-class anti-C5a monoclonal antibody...

Hot of the press: BIOTECH Insight Newsletter
According to the results of the Biotechnology Company Survey 2022 conducted by BIOCOM AG (Berlin), the turnover of the German biotech sector grew...

Cannabis players Canify AS and Bavaria Weed merge to form Canify AG
The merger combines Canify AS’s expertise in the production of pharna-grade medical cannabis with the market position of Bavaria Weed GmbH, as...

Agomab extenses Series B with USD40m Bringing Total Amount to USD114m
Agomab is translating growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore...